美股异动 | Crinetics(CRNX.US)盘初暴涨23% FDA批准其生长激素紊乱治疗方案

Core Insights - Crinetics Pharmaceuticals (CRNX.US) shares surged 23% to a new 8-month high of $44.30 following FDA approval for its drug to treat acromegaly, a rare condition caused by excess growth hormone [1] Company Summary - The FDA approved Crinetics' drug named Palsonify, which is an oral treatment taken once daily [1] - The approval was based on data from two Phase 3 trials, which demonstrated good drug tolerability and provided rapid and consistent biochemical control along with symptom relief [1] - The company anticipates that Palsonify will be launched in the U.S. in early October [1]